ERBB2 and breast carcinoma: As a first-line HER2-directed treatment in patients with advanced breast cancer, the combination of neratinib and paclitaxel has been shown to lower the risk of CNS recurrence by 52%, compared with trastuzumab+paclitaxel [22].